Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-25
2011-10-11
Anderson, James (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S262400
Reexamination Certificate
active
08034834
ABSTRACT:
The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.
REFERENCES:
patent: 5478827 (1995-12-01), Oku et al.
patent: 5624931 (1997-04-01), Oku et al.
patent: 6337342 (2002-01-01), Karabelas et al.
patent: 6492409 (2002-12-01), Karabelas et al.
patent: 2003/0092749 (2003-05-01), Dombroski et al.
patent: 2003/0134886 (2003-07-01), Karabelas et al.
patent: 2004/0106604 (2004-06-01), Beight et al.
patent: 2004/0204426 (2004-10-01), Kubo et al.
patent: 2005/0288347 (2005-12-01), Hodge et al.
patent: 2006/0167070 (2006-07-01), Ying et al.
patent: WO 98/27092 (1998-06-01), None
patent: WO 00/78750 (2000-12-01), None
patent: WO 02/072576 (2002-09-01), None
patent: WO 02/094833 (2002-11-01), None
patent: WO 03/045926 (2003-06-01), None
patent: WO 03/055860 (2003-07-01), None
patent: WO 2004/089415 (2004-10-01), None
patent: WO 2005/000300 (2005-01-01), None
patent: WO 2005/044194 (2005-05-01), None
patent: WO 2005/087750 (2005-09-01), None
patent: WO 2006/055760 (2006-05-01), None
patent: WO 2006/087077 (2006-08-01), None
patent: WO 2008/021364 (2008-02-01), None
patent: WO 2008/051416 (2008-05-01), None
patent: WO 2008/057246 (2008-05-01), None
patent: WO 2008/057246 (2008-05-01), None
Yuksek, Haydar and Ikizler A. A., “Synthesis of 4-Succinimido-4,5-Dihydro-1H-1,2,4-Triazol-5-ones,”Turkish Journal of Chemistry, 18: 57-61 (1994).
Ikizler, A.A. and Yüksek, H., “Acetylation of 4-Amino-4,5-Dihydro-1H-1,2,4-Triazol-5-Ones,”Organic Preparations and Procedures Int., 25(1): 99-139(1993).
Ikizler, A.A. et al., “Synthesis and Biological Activities of Some 4,5-Dihydro-1H-1,2,4-Triazol-5-One Derivatives,”Acta Poloniae Pharmaceuticals—Drug Research, 55(2) 117-123 (1998).
Dymock, B.W., et al., “Inhibitors of HSP90 and Other Chaperones for the Treatment of Cancer,”Expert Opin. Ther. Patents, 14(6): 837-847 (2004).
Bonvini, P., et al., “Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-Client Tyrosine Kinase: Down-Regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK+ CD30 + Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino,17-Demethoxygeldanamycin,”Cancer Research62:1559-1566 (Mar. 1, 2002).
Dias, S.da R., et al., “Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17-Allylamino-17-Demethoxygeldanamycin,”Cancer Research65(23):10686-10691 (Dec. 1, 2005).
George, P., et al., “Combination of the Histone Deacetylase Inhibitor LBH589 and the Hsp90 Inhibitor 17-AAG is Highly Active Against Human CML-BC Cells and AML Cells With Activating Mutation of FLT-3,”Blood105(4):1768-1776 (Feb. 15, 2005).
Lavictoire, S.J., et al., “Interaction of Hsp90 With the Nascent Form of the Mutant Epidermal Growth Factor Receptor EGFRvIII,”J. Biological Chemistry278(7):5292-5299 (Feb. 14, 2003).
Nakatani, H., et al., “STI571 (Glivec) Inhibits the Interaction Between c-KIT and Heat Shock Protein 90 of the Gastrointestinal Stromal Tumor Cell Line, GIST-T1,”Cancer Sci96(2):116-119 (Feb. 2005).
Yao, Q., et al., “FLT3 Expressing Leukemias Are Selectively Sensitive to Inhibitors of the Molecular Chaperone Heat Shock Protein 90 Through Destabilization of Signal Transduction-Associated Kinases,”Clinical Cancer Research9:4483-4493 (Oct. 1, 2003).
Du Zhenjian
Foley Kevin
Anderson James
Davis Steven G.
McCarter & English LLP
Synta Pharmaceuticals Corp.
LandOfFree
Method for treating proliferative disorders with HSP90... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating proliferative disorders with HSP90..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating proliferative disorders with HSP90... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261366